Get the Stockscreener App
70.00
1.39%
0.91
After Hours:
70.00
Apogee Therapeutics Inc stock is traded at $70.00, with a volume of 947.75K.
It is up +1.39% in the last 24 hours and down -3.22% over the past month.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
See More
Previous Close:
$69.09
Open:
$68.23
24h Volume:
947.75K
Relative Volume:
1.01
Market Cap:
$4.78B
Revenue:
-
Net Income/Loss:
$-146.66M
P/E Ratio:
-25.42
EPS:
-2.7541
Net Cash Flow:
$-133.21M
1W Performance:
+2.43%
1M Performance:
-3.22%
6M Performance:
+85.37%
1Y Performance:
+129.45%
1-Day Range:
$66.00
$70.30
1-Week Range:
$66.00
$73.71
52-Week Range:
$26.20
$84.56
Apogee Therapeutics Inc Stock (APGE) Company Profile
Name
Apogee Therapeutics Inc
Sector
Industry
Phone
650-394-5230
Address
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
70.00 | 4.72B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.83 | 121.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.67 | 81.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
766.92 | 47.74B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.76 | 43.93B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
316.99 | 35.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-07-26 | Initiated | Wolfe Research | Peer Perform |
| Dec-17-25 | Initiated | Stephens | Overweight |
| Dec-10-25 | Initiated | Deutsche Bank | Buy |
| Nov-03-25 | Initiated | Craig Hallum | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Sep-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-07-25 | Reiterated | BTIG Research | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Nov-25-24 | Initiated | Canaccord Genuity | Buy |
| May-10-24 | Initiated | BofA Securities | Buy |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | Guggenheim | Buy |
| Aug-08-23 | Initiated | Jefferies | Buy |
| Aug-08-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
| Aug-08-23 | Initiated | Wedbush | Outperform |
View All
Apogee Therapeutics Inc Stock (APGE) Latest News
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million - AOL.com
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million - The Motley Fool
Apogee Therapeutics, Inc. (APGE) Stock Analysis: A Promising Biotech with Nearly 50% Upside Potential - DirectorsTalk Interviews
Apogee Therapeutics to Participate in Upcoming March Conferences - The Manila Times
Apogee Therapeutics (APGE) Expected to Announce Earnings on Monday - Defense World
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction - Yahoo Finance
Aberdeen Group plc Takes Position in Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics Inc. (NASDAQ:APGE) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
What is Apogee Therapeutics Inc. s 5 year growth outlookJuly 2025 Rallies & Stock Market Timing Techniques - mfd.ru
Apogee Therapeutics Rings the Closing Bell - Nasdaq
End of Apogee (APGE) Drug Collaboration Leads to Revised Analyst Expectations - Finviz
Technical Reactions to APGE Trends in Macro Strategies - Stock Traders Daily
Is Apogee Therapeutics (APGE) Now Defined by Its IL-13/OX40L Positioning Against Sanofi? - Yahoo Finance
Here is Why Apogee Therapeutics (APGE) Appears Attractive - Yahoo Finance
CEO Moves: What is Apogee Therapeutics Inc. s 5 year growth outlook2025 Market WrapUp & Weekly Top Gainers Trade List - mfd.ru
Michael Thomas Henderson Sells 20,000 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock - MarketBeat
CEO Michael Henderson Sells 20,000 Shares of Apogee Therapeutics Inc - GuruFocus
Apogee Therapeutics CEO Sells 20,000 Shares - TradingView
What’s the beta of Apogee Therapeutics Inc. stockTrade Volume Report & Technical Pattern Alert System - mfd.ru
Apogee Therapeutics touts quarterly-to-biannual AD dosing shift, expands asthma ambitions at conference - MarketBeat
Page not foundAirwhon - MarketBeat
APGE: Quarterly dosing, rapid itch relief, and strong safety set up a 2029 launch to challenge market leaders - TradingView
Aug Breakouts: Can Apogee Therapeutics Inc. stock outperform in a bear marketJuly 2025 Opening Moves & Daily Volume Surge Trade Alerts - mfd.ru
Candriam S.C.A. Invests $5.01 Million in Apogee Therapeutics Inc. $APGE - MarketBeat
Can Apogee Therapeutics Inc. sustain earnings growth2025 Year in Review & Capital Efficient Trade Techniques - mfd.ru
Apogee Therapeutics stock hits 52-week high at 62.24 USD By Investing.com - Investing.com Australia
Apogee Therapeutics stock hits 52-week high at 62.24 USD - Investing.com
Smart Money: Should I set a stop loss on Lichen International LimitedEarnings Growth Summary & Weekly Top Gainers Alerts - baoquankhu1.vn
Trading the Move, Not the Narrative: (APGE) Edition - Stock Traders Daily
Portfolio Update: What is Apogee Therapeutics Incs 5 year growth outlook2025 Sector Review & Fast Moving Trade Plans - baoquankhu1.vn
Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Insider Selling: Apogee Therapeutics (NASDAQ:APGE) Insider Sells 5,500 Shares of Stock - MarketBeat
Insider Sell: Jane Henderson Sells 2,000 Shares of Apogee Therap - GuruFocus
Apogee Therapeutics CMO sells $361,860 in shares By Investing.com - Investing.com Nigeria
Apogee Therapeutics CMO sells $361,860 in shares - Investing.com
Apogee Therapeutics, Inc. (APGE) Stock Analysis: A 58.9% Potential Upside for Investors in the Biotech Sector - DirectorsTalk Interviews
Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns By Investing.com - Investing.com Canada
Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns - Investing.com
What drives Apogee Therapeutics Inc.’s stock priceEarnings Overview Summary & Low Risk Entry Point Tips - mfd.ru
Fairmount Funds Management LLC Increases Stake in Apogee Therape - GuruFocus
Aug Gainers: Can Apogee Therapeutics Inc stock outperform in a bear marketWeekly Stock Recap & Long-Term Growth Stock Strategies - baoquankhu1.vn
Exane Asset Management Invests $2.05 Million in Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics Inc Stock (APGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):